Project Sage Oldco, Inc.

OTCPK:SIEN.Q Stock Report

Market Cap: US$298.9k

Project Sage Oldco Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Project Sage Oldco.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Apr 17

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Sientra, Inc.'s ( NASDAQ:SIEN ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right now...
Seeking Alpha • Oct 19

Sientra slides 18% on proposes stock offering

Sientra (NASDAQ:SIEN) intends to offer and sell in an underwritten public offering shares of common stock. Each share of common stock will be sold with a warrant to purchase one share of the company’s common stock. Underwriters are granted a 30-day option to purchase additional shares of common stock and/or additional common stock purchase warrants at the public offering price. All of the securities in the offering are to be offered by the Company. Currently, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sientra intends to use any net proceeds received from this offering for general working capital purposes. Sientra stock fell 18.02% after-hours.
Seeking Alpha • Oct 12

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra (NASDAQ:SIEN) rushed to reset its convertible notes financing at premiums as heavy as 272% of the stock's last close. The medical aesthetics firm Sientra told Wednesday it has entered into a $23M new senior secured convertible note refinancing with Deerfield Management at a conversion price of $1, representing a 35% premium on stock's last close. Also, the existing convertible note deal is amended to reduce the debt load by $10M to $50M at reset conversion price of $2.75, a whopping 272% premium on stock's close of $0.74. Maturity date for the existing notes is extended by 12 months to March 2026. "Proceeds from the financing are to be used to retire existing $21M senior secured term loan facility in full, and related financing expenses," the company said. On results front, Sientra reported its third quarter preliminary estimate at $21.5-$22.5M (+10-15%) compared to $21.65M consensus. The company is also reiterating prior full year 2022 revenue guidance of $90-95M vs. consensus of $90.85M. Net cash and cash equivalents anticipated to be $19M and free cash flow to range between $3 to $4M at the end of Q3 2022. "Our growth was driven by robust reconstruction demand and continued market share gains in augmentation. We look forward to continuing this momentum into 2023 and beyond as we prepare to launch our new fat transfer product and ground-breaking Allox2® PRO tissue expander," commented Sientra’s President and Chief Executive Officer Ron Menezes. Seeking Alpha's Quant Rating system assigns Strong Sell to SIEN, which sets the stock analysis stand apart from Wall Street's Strong Buy.
Seeking Alpha • Sep 20

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Sientra (NASDAQ:SIEN) on Tuesday said it had got approval from Saudi Arabia's drug regulator to market its line of silicone gel breast implants in the Middle Eastern country. The Saudi Food & Drug Authority approved the marketing of SIEN's smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants, the company said in a statement. "As the largest country in the Middle East and (the Gulf Cooperation Council), and a growing aesthetics hub for the region, we see the Kingdom of Saudi Arabia as the tremendous launchpad for our international expansion efforts into the Middle East region," said SIEN CEO Ron Menezes. The company will market its breast implants in the GCC through its local partner Rose Aljazera. SIEN stock -4% to $0.56 in premarket trading.
Seeking Alpha • Aug 11

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra press release (NASDAQ:SIEN): Q2 GAAP EPS of -$0.29 misses by $0.06. Revenue of $21.5M (+7.0% Y/Y) misses by $2.26M. Ron Menezes, Sientra’s President and Chief Executive Officer, said, “With our advanced technology, industry-leading safety profile, and innovative programs, we have been able to significantly outperform the market in both reconstruction and augmentation. We are encouraged by the high level of re-order rates we are seeing as well as overall new account growth, which we believe sets us up for continued growth in 2022 and beyond." The company is adjusting full year's revenue guidance to a range of $90M to $95M, down from prior guidance of $93M to $97M and consensus of $95.25M. The new guidance reflects growth of 11% to 18% compared to sales of $80.7M in 2021.
Seeking Alpha • Jul 06

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra (NASDAQ:SIEN) on Wednesday said the U.S. FDA had approved its breast implant product for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. SIEN said the product, Low Plus Profile Projection Breast Implant, would be commercially available for certified and eligible plastic surgeons in the U.S. in late July. SIEN said it would be first implant maker in the U.S. to offer 80cc and 110cc gel implants, with the two new sizes bringing more options to surgeons and their patients. SIEN stock slightly lower in volatile early trading.
Analysis Article • Apr 16

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 06

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Project Sage Oldco has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:SIEN.Q - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202390-59-14-11N/A
6/30/202393-59-14-11N/A
3/31/202392-68-27-23N/A
12/31/202291-73-38-35N/A
9/30/202288-67-48-47N/A
6/30/202285-24-61-58N/A
3/31/202284-24-51-48N/A
12/31/202181-63-47-42N/A
9/30/202176-67-43-37N/A
6/30/202172-97-34-29N/A
3/31/202161-110-50-46N/A
12/31/202055-67-64-60N/A
9/30/202060-67-70-66N/A
6/30/202067-88-89-85N/A
3/31/202079-94-94-90N/A
12/31/201946-58-90-87N/A
9/30/201980-111-92-88N/A
6/30/201974-109-76-74N/A
3/31/201971-90-69-68N/A
12/31/201868-83-57-56N/A
9/30/201860-76-53-52N/A
6/30/201853-70-62-61N/A
3/31/201844-72-52-50N/A
12/31/201737-64-48-46N/A
9/30/201732-54-44-43N/A
6/30/201729-50N/A-31N/A
3/31/201727-40N/A-30N/A
12/31/201621-40N/A-34N/A
9/30/201616-60N/A-38N/A
6/30/201619-57N/A-31N/A
3/31/201627-50N/A-28N/A
12/31/201538-41N/A-18N/A
9/30/201549-16N/A-9N/A
6/30/201549-11N/A-8N/A
3/31/201547-8N/A-2N/A
12/31/201445-6N/A0N/A
9/30/201442-6N/A-6N/A
6/30/201439-11N/A-12N/A
3/31/201437-16N/A-22N/A
12/31/201335-19N/A-26N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SIEN.Q's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if SIEN.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SIEN.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SIEN.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SIEN.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SIEN.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/01 00:44
End of Day Share Price 2024/07/01 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Project Sage Oldco, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle RoseCanaccord Genuity
Kyle BauserColliers Securities
Alexander NowakCraig-Hallum Capital Group LLC